Clinical trial · Observational
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of Hepatocellular Carcionoma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Liquid biopsy technology based on high-throughput sequencing can detect trace signals in the early stage of cancer in plasma free DNA, so it has become a new technology suitable for tumor diagnosis and screening.Relying on the key discipline of digestive liver disease in our hospital, this project cooperated with BGI to jointly carry out a prospective study on the application of liquid biopsy in the monitoring of population at risk of liver cancer by taking advantage of its technical advantages in next-generation sequencing, so as to provide an innovative way for the prevention and treatment of Hepatocellular Carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ultrasonic testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Nodular group
- description
- nodules less than 2 cm in diameter
- interventionNames
- Diagnostic Test: ultrasonic testing
- label
- Macronodular group
- description
- nodules between 2-3 cm in diameter
- interventionNames
- Diagnostic Test: ultrasonic testing
Primary outcomes (2)
- measure
- The establishment of risk assessment model
- timeFrame
- 6-12 months
- description
- The risk assessment model of liver cancer was established to identify the high-risk groups of HCC.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed as chronic liver disease, including but not limited to chronic hepatitis B, chronic hepatitis C, fatty liver; 2. Intrahepatic nodules detectable by ultrasound; 3. Unlimited number of nodules; 4. The patient has signed an informed consent form. Exclusion Criteria: 1. Previously diagnosed malignant tumors； 2. Patients who are unable to cooperate with venous blood sampling； 3. According to the judgment of the investigator, the participants are not suitable to participate in this study.
References
Publications (0)
Data not yet available